-
The innovation of domestic chemical drugs is still continuing, but it is entering the slow lane
Time of Update: 2022-11-11
In addition to Ruoxinlin, according to the data, in October, CDE accepted a total of 85 domestic class 1 new drugs (calculated by acceptance number), including 83 IND applications and 2 NDA applications, involving 40 varieties (according to the dimension of drugs + enterprises), all of which have entered the corresponding sequence of queues for review.
-
Entering the post-medical reform revision stage, pharmaceutical companies need to strengthen innovation and actively deploy overseas
Time of Update: 2022-11-11
In addition, the marketing applications for two new indications of drug H for the first-line treatment of small cell lung cancer and esophageal squamous cell carcinoma were successively accepted by the NMPA in April and August this year.
-
In less than a month, many pharmaceutical stocks rose by more than 60%
Time of Update: 2022-11-11
The market performance of the microelectrophysiology-U range is also very eye-catching, rising as much as 110% in October, and as of the close of November 7, the stock was quoted at 27.
-
Innovative drug research and development is difficult, and the research and development of first-in-class cannot be blind
Time of Update: 2022-11-11
According to the FDA's definition, a drug granted first-in-class designation refers to a drug that uses a completely new and unique mechanism of action to treat a certain disease 。 In recent years, wi
-
The biopharmaceutical industry is developing rapidly, and the import substitution space of domestic chromatography media is broad
Time of Update: 2022-11-04
Biopharmaceutical research in the Asia-Pacific region started late, and downstream separation and purification technology is relatively weak, but with the rapid development of the biopharmaceutical industry in recent years and the expansion of the production capacity of biopharmaceutical CDMO enterprises, the huge R&D and production demand has brought about an increase in the growth rate of chromatography chemistries.
-
CXO demand is growing explosively, and the future layout of enterprises may usher in the golden period of development
Time of Update: 2022-11-04
【Pharmaceutical Network Market Analysis】 In recent years, with the rapid development of China's biopharmaceutical enterprises and the expansion of market capacity, the layout of CXO track enterprises
-
The pharmaceutical sector is changing, and many pharmaceutical stocks are up and down!
Time of Update: 2022-11-04
On the other hand, the company actively explores OEM brand output, commercial distribution, promotes modern logistics extension services, explores new business models such as third-party logistics business, and invests in the construction of traditional Chinese medicine pieces processing base project and other health food production cooperation projects, enters the field of health product production, and continuously lengthens the company's industrial chain.
-
Itching scars on rainy days? Qianbaina scar calming itching scar removal is carried out simultaneously!
Time of Update: 2022-11-04
According to the World Health Organization, from 2007 to 2008, the total caesarean section rate in China was close to 50%, which is more than 3 times the recommended upper limit of the World Health O
-
The Chinese medicine sector changes! A stock out of 2 consecutive boards, what information is released?
Time of Update: 2022-11-04
The industry expects that under the background of the continuous release of national policy dividends, it is expected that the industry will maintain double-digit growth during the "14th Five-Year Plan" period, and the overall scale of the Chinese medicine market can exceed 1 trillion yuan.
-
CDC data shows that the spread of the new Omicron subtype in the United States is accelerating
Time of Update: 2022-11-04
The latest data released on the website of the US Centers for Disease Control and Prevention shows that the proportion of infections caused by the two new subtypes, BQ.
-
The traditional Chinese medicine sector will usher in a double recovery of valuation and performance, and many pharmaceutical companies will hand over satisfactory "report cards"
Time of Update: 2022-11-04
From the third quarter performance report of this year, as of October 31, 74 A-share listed Chinese medicine companies announced the "report card" of the third quarter, of which 29 companies achieved double growth in revenue and net profit attributable to the parent, accounting for 39.
-
The era of innovative Chinese medicine has arrived, and enterprises are expected to continue to benefit
Time of Update: 2022-11-04
"By increasing investment in the research and development of innovative drugs, Yiling Pharmaceutical believes that the development of the company will break the market's value expectations for the traditional Chinese medicine industry in the near future, and the performance growth market is just around the corner.
-
R&D progress is remarkable, new industry layout is orderly, and the advantages of Sinovac Pharmaceutical are fully demonstrated
Time of Update: 2022-11-04
Product registration has accelerated the process of going to sea in an all-round way In recent years, the overseas market demand for high-quality biopharmaceuticals has strengthened, and Sinovac Pharmaceutical has actively established strategic cooperation with domestic and foreign biotechnology companies by relying on more than 20 years of commercialization experience, global three-dimensional marketing network and channel resources, and rapid overseas registration capabilities.
-
Policy and industry resonance Retail pharmacies have expanded their development space
Time of Update: 2022-10-31
js?cdnversion='+~(-new Date()/36e5)]; In recent years, policies involving the adjustment of medical insurance personal accounts, the standardized supervision of licensed pharmacists, centralized procurement with quantity, and hospital outpatient coordination have been successively introduced and actively implemented, and the standardization and importance of the out-of-hospital drug retail market have gradually increased.
-
National Medical Insurance Bureau: The "two-invoice system" will not be abolished for the time being
Time of Update: 2022-10-31
js?cdnversion='+~(-new Date()/36e5)]; A few days ago, the National Medical Insurance Bureau made it clear in the "Letter on the Reply to the Proposal No. 04377 (Medical and Health No. 414) of the Fifth Meeting of the 13th National Committee of the Chinese People's Political Consultative Conference" (hereinafter referred to as the reply letter) that the "two-invoice system" for the procurement of pharmaceutical consumables by medical institutions still plays an important role and is not suitable for cancellation at present.
-
National Health Commission: 11 units pilot to cultivate high-level application-oriented public health talents
Time of Update: 2022-10-31
js?cdnversion='+~(-new Date()/36e5)]; According to the National Health Commission, the state is piloting and implementing high-level application-oriented public health talent training innovation projects in 10 universities including Peking University and Jilin University and the China Center for Disease Control and Prevention.
-
The pharmaceutical sector rose, and many stocks such as Xintian Pharmaceutical touched the limit!
Time of Update: 2022-10-31
Fundamentally, recently in the disclosure period of the third quarterly report of listed companies, a number of medical cosmetology companies disclosed the performance data of the first three quarters, and the net profit increased significantly, such as the strong growth rate of the medical cosmetology sector of East China Medicine, a year-on-year increase of 113.
-
The number of deaths among children with unexplained kidney disease in Indonesia increased to 141
Time of Update: 2022-10-31
(End) Indonesian Health Minister Budi Gunadi Sadikin reported on the 24th that the number of cases of children with unexplained kidney disease in the country has increased to 245, of which 38 people were cured and discharged and 141 died.
-
A new round of medical insurance negotiations is imminent, 19 rare disease drugs have passed the preliminary review, can the bargain be successful?
Time of Update: 2022-10-31
However, before the start of a new round of price negotiations, on October 12, the National Health Insurance Bureau responded to the relevant recommendation: a small number of particularly expensive rare disease drugs obviously exceed the basic medical insurance protection level, and cannot be included in the scope of medical insurance payment.
-
The number of children with respiratory viral infections has soared nationwide
Time of Update: 2022-10-31
(Zhang Yingzhe, reporter of the main station) On the 24th local time, according to CNN and other US media reports, the surge in respiratory syncytial virus (RSV) cases in young children in the United States has overwhelmed some hospitals.
